Patents Assigned to Millennium Pharmaceuticals, Inc.
  • Benzamides and related inhibitors of factor XA
    Patent number: 9629831
    Abstract: Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.
    Type: Grant
    Filed: June 17, 2015
    Date of Patent: April 25, 2017
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Bing-Yan Zhu, Wenrong Huang
  • Indole substituted pyrrolopyrimidinyl inhibitors of Uba6
    Patent number: 9593121
    Abstract: Disclosed are chemical entities that inhibit Uba6, each of which is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R*1 is —H or —CH3; and Y is Formula (II) or Formula (III), wherein R2 is —H, —CH3 or C1-4 alkyloxycarbonyl; and RS7.1, RS7.2 and RS8.1 are defined herein; pharmaceutical compositions comprising the chemical entities; and methods of using the chemical entities. These chemical entities are useful for treating disorders, particularly cell proliferation disorders, including cancers.
    Type: Grant
    Filed: August 2, 2013
    Date of Patent: March 14, 2017
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Benjamin Stone Amidon, David P. Cardin, Alexandra E. Gould, Paul D. Greenspan, Sean J. Harrison
  • METHODS OF TREATMENT OF CANCER
    Publication number: 20170035917
    Abstract: The present invention provides a method of treating cancer with a proteasome inhibitor. The invention provides a method for treating a patient with a proteasome inhibitor based on measurements of tumor features using biomedical imaging techniques. The invention also provides a method of treating a patient with cancer based on levels of GLUT4, as measured by a biomedical imaging technique. The invention also provides a method of treating a cancer patient with a proteasome inhibitor based on the effect of the treatment on tumor features measured by a biomedical imaging technique.
    Type: Application
    Filed: June 10, 2014
    Publication date: February 9, 2017
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Daniel P. BRADLEY, Robbie J. ROBERSTON
  • Pharmaceutical salts and polymorphs of a factor Xa inhibitor
    Patent number: 9555023
    Abstract: The present invention provides for salts comprising a compound of Formula I and an acid that has activity against mammalian factor Xa. The present invention is also directed to methods of making the compound of Formula I.
    Type: Grant
    Filed: May 18, 2015
    Date of Patent: January 31, 2017
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Craig Grant, James P. Kanter, Graeme Langlands
  • Substituted 1,3-thiazoles as synthetic intermediates for preparation of Raf kinase inhibitors
    Patent number: 9556177
    Abstract: The present disclosure provides compounds having Formula II-vi-a: wherein Cy1, Cy2, and A? are defined as set forth in the specification. These compounds are synthetic intermediates used to prepare inhibitors of Raf protein kinase.
    Type: Grant
    Filed: July 28, 2014
    Date of Patent: January 31, 2017
    Assignees: Millennium Pharmaceuticals, Inc., Sunesis Pharmaceuticals, Inc.
    Inventors: Weirong Chen, Benjamin Lane, Hairuo Peng
  • Heterocyclic compounds useful as PDK1 inhibitors
    Patent number: 9546165
    Abstract: The present invention provides compounds useful as inhibitors of PDK1. The present invention also provides compositions thereof, and methods of treating PDK1-mediated diseases.
    Type: Grant
    Filed: October 5, 2010
    Date of Patent: January 17, 2017
    Assignees: Sunesis Pharmaceuticals, Inc., Millennium Pharmaceuticals, Inc.
    Inventors: Joseph Arndt, Timothy Chan, Kevin Guckian, Gnanasambandam Kumaravel, Wen-Cherng Lee, Edward Yin-Shiang Lin, Daniel Scott, Lihong Sun, Jermaine Thomas, Kurt van Vloten, Deping Wang, Lei Zhang, Daniel Erlanson
  • HYDROCHLORIDE SALT OF((1S,2S,4R)-4--2-HYDROXYCYCLOPENTYL) METHYL SULFAMATE
    Publication number: 20170000792
    Abstract: Disclosed is a compound of formula (I): crystalline forms thereof, and solvates thereof; pharmaceutical compositions comprising a pharmaceutically effective amount of the compound of formula (I), or a crystalline form thereof, or a solvate thereof, and a pharmaceutically acceptable carrier or diluent; and the use of a compound of formula (I), or a crystalline form thereof, or a solvate thereof, for treating a patient suffering from, or subject to, a pathological condition capable of being ameliorated by inhibiting an E1 activating enzyme, particularly NAE, including, e.g., cancer.
    Type: Application
    Filed: October 9, 2015
    Publication date: January 5, 2017
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Ian G. Armitage, Reenu Chopra, Martin Ian Cooper, Marianne Langston, Steven P. Langston, Stepan Vyskocil
  • FORMULATION FOR ANTI-ALPHA4BETA7 ANTIBODY
    Publication number: 20170002078
    Abstract: Methods for inducing clinical remission of ulcerative colitis in a human patient are described comprising administration of an antibody that has binding specificity for human ?4?7 integrin using a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-?4?7 antibody in vivo.
    Type: Application
    Filed: July 20, 2016
    Publication date: January 5, 2017
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: IRVING H. FOX, CATHERINE SCHOLZ
  • HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME
    Publication number: 20170002032
    Abstract: Disclosed are chemical entities which are compounds of formula (I): or pharmaceutically acceptable salts thereof; wherein Y, Ra, Ra?, Rb, Rc, X1, X2, X3, Rd, Z1, and Z2 have the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry. Chemical entities according to the disclosure can be useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular, and neurodegenerative diseases or disorders.
    Type: Application
    Filed: June 30, 2015
    Publication date: January 5, 2017
    Applicant: MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Matthew O. Duffey, Dylan England, Scott Freeze, Zhigen Hu, Steven Langston, Charles McIntyre, Hirotake Mizutani, Koji Ono, He Xu
  • HETEROARYL INHIBITORS OF SUMO ACTIVATING ENZYME
    Publication number: 20160355504
    Abstract: Disclosed are compounds of formula (I); or a pharmaceutically acceptable salt thereof; wherein Y, Ra, Ra?, Rc, Rf, X2, Rd, Rd?, Re, Re?2, m, and G have the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry, useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular and neurodegenerative diseases or disorders.
    Type: Application
    Filed: July 1, 2014
    Publication date: December 8, 2016
    Applicant: MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Matthew O. Duffey, Dylan B. England, Zhigen Hu, Mitsuhiro Ito, Steven P. Langston, Charles McIntyre, Hirotake Mizutani, He Xu
  • Pharmaceutical compositions for the treatment of cancer and other diseases or disorders
    Patent number: 9504693
    Abstract: This invention provides novel pharmaceutical compositions of the compound of formula (I): or a pharmaceutically acceptable salt thereof, that are suitable for the bulk production of an oral pharmaceutical dosage form; processes for the production of said oral pharmaceutical dosage form; and the use of the pharmaceutical composition for the treatment of patients suffering from or subject to diseases, disorders, or conditions involving cell survival, proliferation and migration, including chronic inflammatory proliferative disorders, proliferative ocular disorders, benign proliferative disorders, and cancer.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: November 29, 2016
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Vijayalakshmi Ramanan, Irene S. Tobias, Raymond D. Skwierczynski, Dauntel S. Verwijs
  • FORMULATION FOR ANTI-ALPHA4BETA7 ANTIBODY
    Publication number: 20160340431
    Abstract: Methods for maintaining clinical remission of ulcerative colitis in a human patient are described comprising administration of an antibody that has binding specificity for human ?4?7 integrin using a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-?4?7 antibody in vivo.
    Type: Application
    Filed: July 20, 2016
    Publication date: November 24, 2016
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Irving H. Fox, Catherine SCHOLZ
  • FORMULATION FOR ANTI-ALPHA4BETA7 ANTIBODY
    Publication number: 20160340432
    Abstract: Methods for achieving clinical response of Crohn's disease in a human patient are described comprising administration of an antibody that has binding specificity for human ?4?7 integrin using a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-?4?7 antibody in vivo.
    Type: Application
    Filed: July 20, 2016
    Publication date: November 24, 2016
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Irving H. Fox, Catherine Scholz
  • Methods for the identification, assessment, and treatment of patients with cancer therapy
    Patent number: 9500656
    Abstract: The present invention is directed to the identification of predictive markers that can be used to determine whether patients with cancer are expected to demonstrate long term or short term survival times. In particular, the present invention is directed to the use of certain individual and/or combinations of predictive markers, wherein the expression of the predictive markers correlates with expected short term or long term survival. Thus, by examining the expression levels of individual predictive markers and/or predictive markers comprising a marker set, it is possible to determine predicted patient survival.
    Type: Grant
    Filed: August 9, 2007
    Date of Patent: November 22, 2016
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Barbara M. Bryant, Andrew I. Damokosh, George Mulligan
  • ANTIBODIES THAT BIND OV064 AND METHODS OF USE THEREFOR
    Publication number: 20160319030
    Abstract: Antibodies and antigen-binding fragments of antibodies that bind OV064 are disclosed. The antibodies bind an extracellular domain of OV064. Some of the antibodies and antigen-binding fragments bind an epitope on OV064 sufficient to induce internalization. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.
    Type: Application
    Filed: July 21, 2016
    Publication date: November 3, 2016
    Applicant: MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Ole Petter Veiby, John S. Babcook
  • Heteroaryl compounds useful as inhibitors of E1 activating enzymes
    Patent number: 9458108
    Abstract: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.
    Type: Grant
    Filed: August 17, 2015
    Date of Patent: October 4, 2016
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher F. Claiborne, Stephen Critchley, Steven P. Langston, Hirotake Mizutani, Edward J. Olhava, Stephane Peluso, Stepan Vyskocil, Gabriel S. Weatherhead
  • Method for the Prophylaxis or Treatment of Systemic Lupus Erythematosus and/or Lupus Nephritis
    Publication number: 20160250238
    Abstract: The present invention provides a method for the prophylaxis or treatment of systemic lupus erythematosus and/or lupus nephritis in a patient in need thereof, which comprises administering an effective amount of [(1R)-1-({[(2, 5-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl] boronic acid or a citric acid ester thereof, or a pharmaceutically acceptable salt thereof to the patient.
    Type: Application
    Filed: October 2, 2014
    Publication date: September 1, 2016
    Applicant: MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Toru Kawamura, Yasushi Fujitani, Masayuki Takizawa
  • Antibodies that bind OV064 and methods of use therefor
    Patent number: 9421277
    Abstract: Antibodies and antigen-binding fragments of antibodies that bind OV064 are disclosed. The antibodies bind an extracellular domain of OV064. Some of the antibodies and antigen-binding fragments bind an epitope on OV064 sufficient to induce internalization. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.
    Type: Grant
    Filed: April 9, 2014
    Date of Patent: August 23, 2016
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Ole Petter Veiby, John S. Babcook
  • Substituted hydroxamic acids and uses thereof
    Patent number: 9382197
    Abstract: This invention provides compounds of formula (I): wherein ring A, X1, X2, X3, R2, R4b, R10, and G have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention, and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.
    Type: Grant
    Filed: October 16, 2013
    Date of Patent: July 5, 2016
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher Blackburn, Kenneth M. Gigstad, Sean J. Harrison, He Xu
  • Humanized anti-CCR2 antibodies and methods of use therefor
    Patent number: 9353184
    Abstract: The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.
    Type: Grant
    Filed: May 6, 2014
    Date of Patent: May 31, 2016
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Theresa O'Keefe, Paul Ponath